Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2Unknown 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 180Lymphoma 134Sarcoma 80Lymphoma, Large B-Cell, Diffuse 79Precursor Cell Lymphoblastic Leukemia-Lymphoma 70Hodgkin Disease 50Lymphoma, Non-Hodgkin 49Leukemia 41Burkitt Lymphoma 40Lymphoma, Mantle-Cell 37Lymphoma, Follicular 34Neuroblastoma 30Ovarian Neoplasms 26Multiple Myeloma 26Neoplasms 24Lymphoma, Large-Cell, Anaplastic 23Carcinoma, Hepatocellular 23Neoplasm Metastasis 20Lymphoma, Large-Cell, Immunoblastic 19Triple Negative Breast Neoplasms 18HIV Infections 18Urinary Bladder Neoplasms 15Acquired Immunodeficiency Syndrome 15Osteosarcoma 14Liposarcoma 14Leiomyosarcoma 13Histiocytoma, Malignant Fibrous 13Breast Neoplasms, Male 13Lymphoma, B-Cell, Marginal Zone 12Inflammatory Breast Neoplasms 12

Interventions

pegfilgrastim 5NPI 2358 3balugrastim 2Granulocyte Colony-Stimulating Factor 2Drug Therapy 2Doxorubicin 2Docetaxel 2Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Chemotherapy-induced Neutropenia × Doxorubicin × Clear all
NCT01126190 2023-03-28

NEUGR-003

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 3 Completed
381 enrolled 13 charts

Chemotherapy-induced Neutropenia

NCT04227990 2020-01-18

Plinabulin iv Solution in Prevention of TAC Induced Neutropenia

BeyondSpring Pharmaceuticals Inc.

Phase 2 Completed
115 enrolled

Chemotherapy-induced Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡